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In the molecule of the title compound, C14H10FN3O, the
bicyclic quinazoline system is effectively planar, with a mean
deviation from planarity of 0.0140 (3) A ˚ . The quinazoline
heterocyclic system and the adjacent benzene ring make a
dihedral angle of 85.73 (9) . Two intermolecular N—H   N
hydrogen bonds contribute to the stability of the crystal
structure. In addition, a weak  –  stacking interaction
[centroid–centroid distance = 3.902 (2) A ˚ ] is observed.
Related literature
For general background to quinazolines, see: Labuda et al.
(2009). Graves et al. (2002); For the preparation of the title
compound, see: Zhang et al. (2010). For bond-length data, see:






a = 8.0210 (16) A ˚
b = 8.3370 (17) A ˚
c = 17.562 (4) A ˚
V = 1174.4 (4) A ˚ 3
Z =4
Mo K  radiation
  = 0.11 mm
 1
T = 293 K




Absorption correction:   scan
(North et al., 1968)
Tmin = 0.969, Tmax = 0.990
2351 measured reﬂections
1256 independent reﬂections
883 reﬂections with I >2  (I)
Rint = 0.082













 max = 0.12 e A ˚  3
 min =  0.15 e A ˚  3
Table 1
Hydrogen-bond geometry (A ˚ ,  ).
D—H   AD —H H   AD    AD —H   A
N1—H1A   N2
i 0.89 2.67 3.408 (4) 142
N1—H1B   N3
ii 0.89 2.38 3.205 (4) 154
Symmetry codes: (i) x þ 1
2; y   1
2; z þ 1; (ii)  x þ 1
2; y;z   1
2.
Data collection: CAD-4 EXPRESS (Enraf–Nonius, 1994); cell
reﬁnement: CAD-4 EXPRESS; data reduction: XCAD4 (Harms &
Wocadlo, 1995); program(s) used to solve structure: SHELXS97
(Sheldrick, 2008); program(s) used to reﬁne structure: SHELXL97
(Sheldrick, 2008); molecular graphics: SHELXTL (Sheldrick, 2008);
software used to prepare material for publication: SHELXL97 and
PLATON (Spek, 2009).
The authors thank the Center of Testing and Analysis,
Nanjing University, for the data collection.
Supplementary data and ﬁgures for this paper are available from the
IUCr electronic archives (Reference: ZL2317).
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